Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy
The RIG-I pathway can be activated by RNA containing 5' triphosphate, leading to type I interferon release and immune activation. Hence, RIG-I agonists have been used to induce immune responses against cancer as potential immunotherapy. However, delivery of 5' triphosphorylated RNA molecul...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
其他作者: | |
格式: | Article |
語言: | English |
出版: |
2022
|
主題: | |
在線閱讀: | https://hdl.handle.net/10356/163208 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|